Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Impairment of blood brain barrier is related with the neuroinflammation induced peripheral immune status in intracerebroventricular colchicine injected rats: An experimental study with mannitol

(2016) Susmita Sil et al.   BRAIN RESEARCH

Pentameric models as alternative molecular targets for the design of new antiaggregant agents

(2016) Exequiel E. Barrera Guisasola et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain

(2016) Kapil Gadkar et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

(2016) Marielle Delnomdedieu et al.   Alzheimers Research & Therapy

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Structure of ring-shaped Aβ42 oligomers determined by conformational selection

(2016) Linh Tran et al.   Scientific Reports

Neurodegenerative Diseases: Expanding the Prion Concept

(2015) Lary C. Walker et al.   Annual Review of Neuroscience

Antibody therapies and their challenges in the treatment of age-related macular degeneration

(2015) Cornelia Volz et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Prefibrillar huntingtin oligomers isolated from HD brain potently seed amyloid formation

(2015) Olga A. Morozova et al.   FEBS LETTERS

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Interaction between therapeutic interventions for Alzheimer’s disease and physiological Aβ clearance mechanisms

(2015) Christopher D. Morrone et al.   Frontiers in Aging Neuroscience

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

(2015) Jacopo C. DiFrancesco et al.   Frontiers in Neurology

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

(2014) Jeffrey Cummings et al.   Alzheimers & Dementia

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

The Structure of Misfolded Amyloidogenic Dimers: Computational Analysis of Force Spectroscopy Data

(2014) Yuliang Zhang et al.   BIOPHYSICAL JOURNAL

Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease

(2014) Kris Simone Tranches Dias et al.   Current Neuropharmacology

Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

(2014) Norman Relkin   JOURNAL OF CLINICAL IMMUNOLOGY

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

X-ray Crystallographic Structures of Trimers and Higher-Order Oligomeric Assemblies of a Peptide Derived from Aβ17–36

(2014) Ryan K. Spencer et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease

(2014) Shichun Tu et al.   Molecular Neurodegeneration

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

(2014) Thomas Leyhe et al.   Alzheimers Research & Therapy

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

(2014) William F Goure et al.   Alzheimers Research & Therapy

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

(2014) Lars Lannfelt et al.   Alzheimers Research & Therapy

The genetics of Alzheimer's disease

(2014) Eva Bagyinszky et al.   Clinical Interventions in Aging

The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries

(2014) Johan Lundkvist et al.   Frontiers in Pharmacology

ACU-193: A candidate therapeutic antibody that selectively targets soluble beta-amyloid oligomers

(2013) Grant Krafft et al.   Alzheimers & Dementia

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

(2013) Izuru Miyoshi et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Mouse platforms jostle for slice of humanized antibody market

(2013) Nuala Moran   NATURE BIOTECHNOLOGY

Cu2+ Affects Amyloid-β (1–42) Aggregation by Increasing Peptide-Peptide Binding Forces

(2013) Francis Hane et al.   PLoS One

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

(2013) Luke A. Miles et al.   Scientific Reports

Evidence for impaired amyloid β clearance in Alzheimer's disease

(2013) Kristin R Wildsmith et al.   Alzheimers Research & Therapy

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization

(2012) I. W. Hamley   CHEMICAL REVIEWS

Amyloid-β Immunotherapy for Alzheimers Disease

(2012) H.J. Fu et al.   CNS & Neurological Disorders-Drug Targets

Microglia and Inflammation in Alzheimers Disease

(2012) Shweta Mandrekar-Colucci et al.   CNS & Neurological Disorders-Drug Targets

The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease

(2012) Miguel Divino da Rocha et al.   CNS & Neurological Disorders-Drug Targets

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Synaptic changes in Alzheimer’s disease and its models

(2012) J. Pozueta et al.   NEUROSCIENCE

Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation

(2012) Dag Sehlin et al.   PLoS One

Molecular basis of  -amyloid oligomer recognition with a conformational antibody fragment

(2012) I. Morgado et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aβ(39–42) Modulates Aβ Oligomerization but Not Fibril Formation

(2011) Megan Murray Gessel et al.   BIOCHEMISTRY

Soluble Aβ oligomer production and toxicity

(2011) Megan E. Larson et al.   JOURNAL OF NEUROCHEMISTRY

Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers

(2011) Rakez Kayed et al.   Molecular Neurodegeneration

Structure-based design of conformation- and sequence-specific antibodies against amyloid  

(2011) J. M. Perchiacca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

(2011) Y. J. Yu et al.   Science Translational Medicine

Characterization of the Interaction of β-Amyloid with Transthyretin Monomers and Tetramers

(2010) Jiali Du et al.   BIOCHEMISTRY

Polymorphism in Alzheimer Aβ Amyloid Organization Reflects Conformational Selection in a Rugged Energy Landscape

(2010) Yifat Miller et al.   CHEMICAL REVIEWS

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

(2010) Inna Kuperstein et al.   EMBO JOURNAL

Bapineuzumab

(2010) Geoffrey A Kerchner et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Generation and Therapeutic Efficacy of Highly Oligomer-Specific  -Amyloid Antibodies

(2010) H. Hillen et al.   JOURNAL OF NEUROSCIENCE

Transmembrane Structures for Alzheimer’s Aβ1−42Oligomers

(2010) Birgit Strodel et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide

(2010) Remy Robert et al.   MOLECULAR IMMUNOLOGY

Beneficial Catalytic Immunity to Aβ Peptide

(2010) Sudhir Paul et al.   REJUVENATION RESEARCH

A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain

(2009) Floyd Sarsoza et al.   ACTA NEUROPATHOLOGICA

Abeta-oligomer selective antibody A-887755 exhibits a favorable profile for Alzheimer's disease immunotherapy compared to Abeta-peptide unselective antibodies

(2009) Stefan Barghorn et al.   Alzheimers & Dementia

Polymorphism of Alzheimer's Aβ17-42 (p3) Oligomers: The Importance of the Turn Location and Its Conformation

(2009) Yifat Miller et al.   BIOPHYSICAL JOURNAL

Structure-neurotoxicity relationships of amyloid  -protein oligomers

(2009) K. Ono et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Energy landscapes of the monomer and dimer of the Alzheimer’s peptide Aβ(1–28)

(2008) Xiao Dong et al.   JOURNAL OF CHEMICAL PHYSICS

Amyloid   Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

(2008) I. Klyubin et al.   JOURNAL OF NEUROSCIENCE

Computational Study on the Structural Diversity of Amyloid Beta Peptide (Aβ10-35) Oligomers

(2008) Soonmin Jang et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease

(2008) Melanie Meyer-Luehmann et al.   NATURE

Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons

(2008) P.J. Shughrue et al.   NEUROBIOLOGY OF AGING

Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools

(2007) Peter Lichtlen et al.   JOURNAL OF NEUROCHEMISTRY